LAURA完成了EGFR+ NSCLC从IB期到IV期的奥西替尼治疗拼图:与安慰剂相比,辅助奥西替尼显著改善不可切除的III期EGFR突变NSCLC的PFS和CNS进展(LAURA, NCT03521154)。

IF 5.1 Q1 ONCOLOGY
Lung Cancer: Targets and Therapy Pub Date : 2025-04-25 eCollection Date: 2025-01-01 DOI:10.2147/LCTT.S520833
Faustine X Luo, Zhaohui Arter, Sai-Hong Ignatius Ou, Misako Nagasaka
{"title":"LAURA完成了EGFR+ NSCLC从IB期到IV期的奥西替尼治疗拼图:与安慰剂相比,辅助奥西替尼显著改善不可切除的III期EGFR突变NSCLC的PFS和CNS进展(LAURA, NCT03521154)。","authors":"Faustine X Luo, Zhaohui Arter, Sai-Hong Ignatius Ou, Misako Nagasaka","doi":"10.2147/LCTT.S520833","DOIUrl":null,"url":null,"abstract":"<p><p>The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, based on the PACIFIC trial (NCT02125461). However, the utility of durvalumab in <i>EGFR</i>-mutated lung cancer patients is questionable based on post-hoc analysis and multi-institutional retrospective analysis. Osimertinib is a third-generation <i>EGFR</i>-tyrosine kinase inhibitor (TKI) with proven clinical efficacy in NSCLC. Given that durvalumab showed no benefit in unresectable Stage III <i>EGFR</i>-mutated NSCLC, it is exciting that most recently, the LAURA trial has demonstrated promising outcomes with adjuvant osimertinib in unresectable, stage III <i>EGFR</i>-mutated NSCLC after definitive chemoradiotherapy with significant improvement in PFS compared to placebo. Furthermore, the LAURA trial demonstrates that osimertinib has a protective effect against distant metastases and CNS progression in this patient population. Here, we explore the results of the LAURA trial and how it transforms the standard-of-care treatment for patients with unresectable, stage III <i>EGFR</i>-mutated NSCLC moving forward.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"16 ","pages":"51-55"},"PeriodicalIF":5.1000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044223/pdf/","citationCount":"0","resultStr":"{\"title\":\"LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of <i>EGFR</i>+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III <i>EGFR</i>-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).\",\"authors\":\"Faustine X Luo, Zhaohui Arter, Sai-Hong Ignatius Ou, Misako Nagasaka\",\"doi\":\"10.2147/LCTT.S520833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, based on the PACIFIC trial (NCT02125461). However, the utility of durvalumab in <i>EGFR</i>-mutated lung cancer patients is questionable based on post-hoc analysis and multi-institutional retrospective analysis. Osimertinib is a third-generation <i>EGFR</i>-tyrosine kinase inhibitor (TKI) with proven clinical efficacy in NSCLC. Given that durvalumab showed no benefit in unresectable Stage III <i>EGFR</i>-mutated NSCLC, it is exciting that most recently, the LAURA trial has demonstrated promising outcomes with adjuvant osimertinib in unresectable, stage III <i>EGFR</i>-mutated NSCLC after definitive chemoradiotherapy with significant improvement in PFS compared to placebo. Furthermore, the LAURA trial demonstrates that osimertinib has a protective effect against distant metastases and CNS progression in this patient population. Here, we explore the results of the LAURA trial and how it transforms the standard-of-care treatment for patients with unresectable, stage III <i>EGFR</i>-mutated NSCLC moving forward.</p>\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":\"16 \",\"pages\":\"51-55\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044223/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S520833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S520833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

基于PACIFIC试验(NCT02125461),目前不可切除的III期非小细胞肺癌(NSCLC)的护理标准包括并行铂基双重化疗和胸部放疗,随后使用durvalumab(一种抗程序性死亡配体1 (PD-L1)抗体)进行强化治疗。然而,基于事后分析和多机构回顾性分析,durvalumab在egfr突变肺癌患者中的应用值得怀疑。奥西替尼是第三代egfr -酪氨酸激酶抑制剂(TKI),在非小细胞肺癌中具有临床疗效。鉴于durvalumab在不可切除的III期egfr突变的NSCLC中没有显示出任何益处,令人兴奋的是,最近的LAURA试验显示,在确定的放化疗后,辅助奥西替尼在不可切除的III期egfr突变的NSCLC中有希望的结果,与安慰剂相比,PFS有显着改善。此外,LAURA试验表明,奥西替尼对该患者群体的远处转移和中枢神经系统进展具有保护作用。在这里,我们探讨了LAURA试验的结果,以及它如何改变不可切除的III期egfr突变NSCLC患者的标准治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).

The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, based on the PACIFIC trial (NCT02125461). However, the utility of durvalumab in EGFR-mutated lung cancer patients is questionable based on post-hoc analysis and multi-institutional retrospective analysis. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI) with proven clinical efficacy in NSCLC. Given that durvalumab showed no benefit in unresectable Stage III EGFR-mutated NSCLC, it is exciting that most recently, the LAURA trial has demonstrated promising outcomes with adjuvant osimertinib in unresectable, stage III EGFR-mutated NSCLC after definitive chemoradiotherapy with significant improvement in PFS compared to placebo. Furthermore, the LAURA trial demonstrates that osimertinib has a protective effect against distant metastases and CNS progression in this patient population. Here, we explore the results of the LAURA trial and how it transforms the standard-of-care treatment for patients with unresectable, stage III EGFR-mutated NSCLC moving forward.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信